{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT05609812","orgStudyIdInfo":{"id":"VT-001-0070"},"organization":{"fullName":"Vera Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Atacicept in Subjects With Active Lupus Nephritis (COMPASS)","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis","acronym":"COMPASS"},"statusModule":{"statusVerifiedDate":"2024-10","overallStatus":"WITHDRAWN","whyStopped":"Study recruitment is paused due to business reasons, but not due to regulatory or safety concerns.","startDateStruct":{"date":"2022-11-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-12-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-11-02","studyFirstSubmitQcDate":"2022-11-07","studyFirstPostDateStruct":{"date":"2022-11-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-19","lastUpdatePostDateStruct":{"date":"2025-05-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vera Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.","detailedDescription":"The study will assess atacicept vs. placebo on the impact of renal function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period."},"conditionsModule":{"conditions":["Lupus Nephritis (LN)"],"keywords":["Systemic Lupus erythematosus (SLE)","estimated glomerular filtration rate (eGFR)","protenuria"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Atacicept Dose","type":"EXPERIMENTAL","description":"Atacicept Dose once weekly subcutaneous (SC) Injection","interventionNames":["Drug: Atacicept"]},{"label":"Placebo to match Atacicept","type":"PLACEBO_COMPARATOR","description":"Placebo to match Atacicept once weekly subcutaneous (SC) injection","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Atacicept","description":"Once weekly subcutaneous (SC) injections by prefilled syringe","armGroupLabels":["Atacicept Dose"],"otherNames":["VT-001"]},{"type":"DRUG","name":"Placebo","description":"placebo","armGroupLabels":["Placebo to match Atacicept"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Renal Response as definedas UPCR ≤0.5 mg/mg, and eGFR ≥60 mL/min/1.73 m^2 or eGFR <60 mL/min/1.73 m^2 with no confirmed decrease from baseline of >20%","timeFrame":"Week 52"}],"secondaryOutcomes":[{"measure":"Renal Response with alternative success criteria","timeFrame":"Weeks 52 and 104"},{"measure":"Time to UPCR of≤0.5 mg/mg","timeFrame":"Week 52"},{"measure":"Renal Response at Week 104","timeFrame":"Week 104"},{"measure":"Time to Death or Renal-Related Event","timeFrame":"Week 104"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Male or Female at least 18 years of age at time of signing consent\n2. Must have the ability to understand and sign and date a written informed consent form\n3. Diagnosis of SLE\n4. Biopsy- Proven Active LN\n5. Requires high-dose corticosteroids and immunosuppressive therapy for the treatment of active LN\n6. Subject is willing to take oral MMF for the duration of the study\n\nKey Exclusion Criteria:\n\n1. eGFR of ≤30 mL/min/1.73 m2.\n2. Sclerosis in 50% of glomeruli on renal biopsy.\n3. Evidence of rapidly progressive glomerulonephritis.\n4. Currently requiring renal dialysis or expected to require dialysis during the study.\n5. Serum igG \\<7 g/L\n6. Active infection or high infectious risk","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Joanne Curley","affiliation":"Chief Development Officer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Vera Site # 0139","city":"Huntsville","state":"Alabama","zip":"35805","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Vera Site # 0138","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Vera Site # 0127","city":"La Palma","state":"California","zip":"90623","country":"United States","geoPoint":{"lat":33.8464,"lon":-118.04673}},{"facility":"Vera Site # 0129","city":"Long Beach","state":"California","zip":"90822","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Vera Site # 0135","city":"Northridge","state":"California","zip":"91324","country":"United States","geoPoint":{"lat":34.22834,"lon":-118.53675}},{"facility":"Vera Site # 0136","city":"Northridge","state":"California","zip":"91324","country":"United States","geoPoint":{"lat":34.22834,"lon":-118.53675}},{"facility":"Vera Site # 0130","city":"Santa Clarita","state":"California","zip":"91321","country":"United States","geoPoint":{"lat":34.39166,"lon":-118.54259}},{"facility":"Vera Site # 0131","city":"Torrance","state":"California","zip":"90502","country":"United States","geoPoint":{"lat":33.83585,"lon":-118.34063}},{"facility":"Vera Site # 0143","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Vera Site # 0140","city":"Gainesville","state":"Florida","zip":"32610","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"Vera Site # 0128","city":"Miami","state":"Florida","zip":"33125","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Vera Site # 0134","city":"Atlanta","state":"Georgia","zip":"30309","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Vera Site # 0137","city":"Augusta","state":"Georgia","zip":"30912","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"Vera Site # 0144","city":"Augusta","state":"Georgia","zip":"30912","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"Vera Site # 0147","city":"Lawrenceville","state":"Georgia","zip":"30046","country":"United States","geoPoint":{"lat":33.95621,"lon":-83.98796}},{"facility":"Vera Site # 0109","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Vera Site # 0133","city":"Las Vegas","state":"Nevada","zip":"89106","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Vera Site # 0149","city":"Summit","state":"New Jersey","zip":"07901","country":"United States","geoPoint":{"lat":40.71562,"lon":-74.36468}},{"facility":"Vera Site # 0146","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Vera Site # 0142","city":"New York","state":"New York","zip":"10039","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Vera Site # 0148","city":"Cleveland","state":"Ohio","zip":"44109","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Vera Site # 0145","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Vera SIte # 0132","city":"Jackson","state":"Tennessee","zip":"38305","country":"United States","geoPoint":{"lat":35.61452,"lon":-88.81395}},{"facility":"Vera Site # 0125","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Vera Site # 0126","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Vera Site # 0122","city":"El Paso","state":"Texas","zip":"79925","country":"United States","geoPoint":{"lat":31.75872,"lon":-106.48693}},{"facility":"Vera Site # 0141","city":"Coto Laurel","zip":"00780","country":"Puerto Rico","geoPoint":{"lat":18.04969,"lon":-66.55128}},{"facility":"Vera Site # 0349","city":"A Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Vera Site # 0348","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Vera Site # 0347","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Vera Site #0351","city":"Santander","zip":"39008","country":"Spain","geoPoint":{"lat":43.46589,"lon":-3.80493}},{"facility":"Vera Site # 0350","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Vera Site # 0346","city":"Valencia","zip":"4601","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Vera Therapeutics, Inc. Company Website","url":"http://veratx.com"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D008181","term":"Lupus Nephritis"},{"id":"D008180","term":"Lupus Erythematosus, Systemic"}],"ancestors":[{"id":"D005921","term":"Glomerulonephritis"},{"id":"D009393","term":"Nephritis"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D003240","term":"Connective Tissue Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C524618","term":"TACI receptor-IgG Fc fragment fusion protein"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07020923","orgStudyIdInfo":{"id":"VT-001-0020"},"organization":{"fullName":"Vera Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Monthly Dosing of Atacicept in IgAN","officialTitle":"A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN"},"statusModule":{"statusVerifiedDate":"2025-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-05-13","studyFirstSubmitQcDate":"2025-06-05","studyFirstPostDateStruct":{"date":"2025-06-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-06-17","lastUpdatePostDateStruct":{"date":"2025-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vera Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept","detailedDescription":"This Phase 2 study is to explore the effectiveness, safety and tolerability of different dosing regimens of atacicept. Regimens include monthly and weekly dosing."},"conditionsModule":{"conditions":["IgA Nephropathy (IgAN)","Berger Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":90,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Atacicept Arm 1","type":"EXPERIMENTAL","description":"Atacicept dose A administered subcutaneous (sc) injection monthly","interventionNames":["Drug: Atacicept"]},{"label":"Atacicept Arm 2","type":"EXPERIMENTAL","description":"Atacicept dose B administered subcutaneous (sc) injection monthly"},{"label":"Atacicept Arm 3","type":"EXPERIMENTAL","description":"Atacicept dose C administered subcutaneous (sc) injection monthly"},{"label":"Atacicept Arm 4","type":"EXPERIMENTAL","description":"Atacicept dose D administered subcutaneous (sc) injection weekly"},{"label":"Atacicept Arm 5","type":"EXPERIMENTAL","description":"Atacicept dose E administered subcutaneous (sc) injection weekly for 24 weeks, followed by monthly sc injections"}],"interventions":[{"type":"DRUG","name":"Atacicept","description":"Drug: Atacicept","armGroupLabels":["Atacicept Arm 1"],"otherNames":["VT-001"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN","description":"Gd-IgA1 levels through Week 24","timeFrame":"Up to 24 weeks"}],"secondaryOutcomes":[{"measure":"To evaluate the safety and tolerability of atacicept at different dosing regimensT","description":"Incidence of treatment emergent reported Adverse Events (AE)","timeFrame":"Baseline until end of study up to Week 24"},{"measure":"To evaluate the effect of atacicept on serum immunoglobulins (IgA)","description":"IgA levels through Week 24","timeFrame":"24 Weeks"},{"measure":"To evaluate the effect of atacicept on serum immunoglobulins (IgG)","description":"IgG levels through Week 24","timeFrame":"24 Weeks"},{"measure":"To evaluate the effect of atacicept on serum immunoglobulins (IgM)","description":"IgM levels through Week 24","timeFrame":"24 Weeks"},{"measure":"To evaluate serum PK of atacicept","description":"Serum concentration of atacicept","timeFrame":"Baseline until end of study up to Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study assessments\n* Adult male or female of ≥18 years of age, or as per country specific legally or nationally recognized adult age, who provides written informed consent prior to performing any study assessments\n* Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years\n* Total urine protein excretion ≥0.75 g per 24-hour or urine protein-to-creatinine ratio (UPCR) ≥0.75 mg/mg based on a 24-hour urine sample\n* eGFR ≥30 mL/min/1.73 m2 at screening, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)\n* On a stable prescribed regimen of RASi (angiotensin converting enzyme inhibitor or angiotensin II receptor blocker) for at least 8 weeks that is at the maximum labeled or tolerated dose at screening and from screening to study Day 1\n\nExclusion Criteria:\n\n* IgAN secondary to another condition (eg, liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (ie, Henoch-Schonlein purpura), systemic lupus erythematosus, dermatitis herpetiformis, ankylosing spondylitis\n* Evidence of rapidly progressive glomerulonephritis (loss of ≥50% of eGFR within 3 months of screening)\n* Evidence of nephrotic syndrome within 6 months of screening (serum albumin \\<3.0 g/dL in association with UPCR \\>3.5 mg/mg)\n* Renal or other organ transplantation prior to or expected during the study, with the exception of corneal transplants\n* Concomitant chronic renal disease in addition to IgAN (eg, diabetic nephropathy, primary focal segmental glomerulosclerosis, membranous nephropathy, C3 glomerulopathy, lupus nephritis)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Vera Therapeutics, Inc. Clinical Trials Information","role":"CONTACT","phone":"(650)770-0077","email":"clinicaltrials@veratx.com"}],"overallOfficials":[{"name":"Zeeshan Khawaja","affiliation":"Vice President, Clinical Development","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Vera Therapeutics","status":"RECRUITING","city":"Brisbane","state":"California","zip":"94005","country":"United States","contacts":[{"name":"Brisbane, California","role":"CONTACT","phone":"(650) 770-0077","email":"clinicaltrials@veratx.com"}],"geoPoint":{"lat":37.68077,"lon":-122.39997}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Vera Therapeutics, Inc Company Website","url":"http://www.veratx.com"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D005922","term":"Glomerulonephritis, IGA"}],"ancestors":[{"id":"D005921","term":"Glomerulonephritis"},{"id":"D009393","term":"Nephritis"},{"id":"D007674","term":"Kidney Diseases"},{"id":"D014570","term":"Urologic Diseases"},{"id":"D052776","term":"Female Urogenital Diseases"},{"id":"D005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D052801","term":"Male Urogenital Diseases"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C524618","term":"TACI receptor-IgG Fc fragment fusion protein"}]}},"hasResults":false}
]}